

Analytical Results For:

 WHITING OIL & GAS
 BRIAN HOLLADAY
 400 W. ILLINOIS, SUITE 1300
 MIDLAND TX, 79701
 Fax-To: NONE

30-021-20588

 Received: 04/23/2014
 Reported: 04/30/2014
 Project Name: WEST BRAVO DOME CO2
 Project Number: 13-1224-03
 Project Location: HARDING COUNTY, NM

 Sampling Date: 04/22/2014
 Sampling Type: Soil
 Sampling Condition: Cool & Intact
 Sample Received By: Jodi Henson

Sample ID: HAZEN 1928 #24-1 (H401230-09)

BTEX 8260B

mg/kg

Analyzed By: ck

Analyte	Result	Reporting Limit	Analyzed	Method Blank	BS	% Recovery	True Value QC	RPD	Qualifier
Benzene*	<0.100	0.100	04/29/2014	ND	2.35	118	2.00	6.15	
Toluene*	<0.050	0.050	04/29/2014	ND	2.13	106	2.00	8.09	
Ethylbenzene*	<0.050	0.050	04/29/2014	ND	2.03	102	2.00	7.15	
Total Xylenes*	<0.150	0.150	04/29/2014	ND	6.25	104	6.00	8.15	
Total BTEX	<0.300	0.300	04/29/2014	ND					

Surrogate: Dibromofluoromethane 104 % 61.3-142

Surrogate: Toluene-d8 97.8 % 71.3-129

Surrogate: 4-Bromofluorobenzene 108 % 65.7-141

Chloride, SM4500Cl-B

mg/kg

Analyzed By: AP

Analyte	Result	Reporting Limit	Analyzed	Method Blank	BS	% Recovery	True Value QC	RPD	Qualifier
Chloride	48.0	16.0	04/25/2014	ND	416	104	400	0.00	

TPH 8015M

mg/kg

Analyzed By: CK

Analyte	Result	Reporting Limit	Analyzed	Method Blank	BS	% Recovery	True Value QC	RPD	Qualifier
GRO C6-C10	<10.0	10.0	04/25/2014	ND	186	92.9	200	11.1	
DRO >C10-C28	21.5	10.0	04/25/2014	ND	207	103	200	12.5	


Surrogate: 1-Chlorooctane 112 % 65.2-140

Surrogate: 1-Chlorooctadecane 109 % 63.6-154

Cardinal Laboratories

*=Accredited Analyte

PLEASE NOTE: Liability and Damages. Cardinal's liability and client's exclusive remedy for any claim arising, whether based in contract or tort, shall be limited to the amount paid by client for analyses. All claims, including those for negligence and any other cause whatsoever shall be deemed waived unless made in writing and received by Cardinal within thirty (30) days after completion of the applicable service. In no event shall Cardinal be liable for incidental or consequential damages, including, without limitation, business interruptions, loss of use, or loss of profits incurred by client, its subsidiaries, affiliates or successors arising out of or related to the performance of the services hereunder by Cardinal, regardless of whether such claim is based upon any of the above stated reasons or otherwise. Results relate only to the samples identified above. This report shall not be reproduced except in full with written approval of Cardinal Laboratories.



Celey D. Keene, Lab Director/Quality Manager